{"id":8714,"date":"2024-02-20T22:01:31","date_gmt":"2024-02-20T14:01:31","guid":{"rendered":"https:\/\/flcube.com\/?p=8714"},"modified":"2024-10-22T22:11:43","modified_gmt":"2024-10-22T14:11:43","slug":"gsk-and-peers-respond-to-ftc-criticism-withdraw-patent-listings-from-us-orange-book","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=8714","title":{"rendered":"GSK and Peers Respond to FTC Criticism, Withdraw Patent Listings from US Orange Book"},"content":{"rendered":"\n

Three pharmaceutical companies, including the UK’s GSK (NYSE: GSK<\/a>), have responded to the Federal Trade Commission’s (FTC) allegations of “abusive” patents by withdrawing several listings from the US Orange Book. This action follows the FTC’s challenge in November against over 100 patents held by manufacturers of branded asthma inhalers, epinephrine autoinjectors, and other pharmaceutical products. The FTC claimed these patents were improperly or inaccurately listed in the US FDA\u2019s “Approved Drug Products with Therapeutic Equivalence Evaluations,” also known as the “Orange Book,” potentially obstructing the entry of generic competitors and inflating drug prices.<\/p>\n\n\n\n

The FTC’s initiative was prompted by US Representative Pramila Jayapal (D-Wash.) and US Senator Elizabeth Warren (D-Mass.), who have released a new letter detailing the companies’ responses to the FTC’s accusations. According to the letter, GSK has addressed the FTC’s criticisms by delisting 12 of the 14 patents identified by the FTC, as well as an additional five patents due to evolving policies and legal developments concerning drug-device combination listings.<\/p>\n\n\n\n

Manufacturers Kal\u00e9o and Amneal have indicated they will delist all patents challenged by the FTC, plus an additional five patents in total (three for Kal\u00e9o and two for Amneal). However, several other companies, including Boehringer Ingelheim, AbbVie, Teva, AstraZeneca, and Viatris, have declined to delist any of the patents identified by the FTC.<\/p>\n\n\n\n

The letter’s authors state, “This was a remarkable success for the FTC, with drug manufacturers announcing the withdrawal of 27 challenged patents within weeks of being asked to do so. At the same time, this rapid response reveals the extent to which drug manufacturers have been blatantly misusing the patent system and gaming FDA\u2019s Orange Book policies, demonstrating that more work remains.”- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Three pharmaceutical companies, including the UK’s GSK (NYSE: GSK), have responded to the Federal Trade…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,61,4],"tags":[184,914],"class_list":["post-8714","post","type-post","status-publish","format-standard","hentry","category-company","category-legal-ip","category-policy-regulatory","tag-gsk","tag-nyse-gsk"],"yoast_head":"\nGSK and Peers Respond to FTC Criticism, Withdraw Patent Listings from US Orange Book - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Three pharmaceutical companies, including the UK's GSK (NYSE: GSK), have responded to the Federal Trade Commission's (FTC) allegations of "abusive" patents by withdrawing several listings from the US Orange Book. This action follows the FTC's challenge in November against over 100 patents held by manufacturers of branded asthma inhalers, epinephrine autoinjectors, and other pharmaceutical products. The FTC claimed these patents were improperly or inaccurately listed in the US FDA\u2019s "Approved Drug Products with Therapeutic Equivalence Evaluations," also known as the "Orange Book," potentially obstructing the entry of generic competitors and inflating drug prices.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=8714\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GSK and Peers Respond to FTC Criticism, Withdraw Patent Listings from US Orange Book\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=8714\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-02-20T14:01:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-22T14:11:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8714#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8714\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GSK and Peers Respond to FTC Criticism, Withdraw Patent Listings from US Orange Book\",\"datePublished\":\"2024-02-20T14:01:31+00:00\",\"dateModified\":\"2024-10-22T14:11:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8714\"},\"wordCount\":302,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"GSK\",\"NYSE: GSK\"],\"articleSection\":[\"Company\",\"Legal \\\/ IP\",\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=8714#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8714\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=8714\",\"name\":\"GSK and Peers Respond to FTC Criticism, Withdraw Patent Listings from US Orange Book - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-02-20T14:01:31+00:00\",\"dateModified\":\"2024-10-22T14:11:43+00:00\",\"description\":\"Three pharmaceutical companies, including the UK's GSK (NYSE: GSK), have responded to the Federal Trade Commission's (FTC) allegations of \\\"abusive\\\" patents by withdrawing several listings from the US Orange Book. This action follows the FTC's challenge in November against over 100 patents held by manufacturers of branded asthma inhalers, epinephrine autoinjectors, and other pharmaceutical products. The FTC claimed these patents were improperly or inaccurately listed in the US FDA\u2019s \\\"Approved Drug Products with Therapeutic Equivalence Evaluations,\\\" also known as the \\\"Orange Book,\\\" potentially obstructing the entry of generic competitors and inflating drug prices.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8714#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=8714\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8714#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GSK and Peers Respond to FTC Criticism, Withdraw Patent Listings from US Orange Book\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GSK and Peers Respond to FTC Criticism, Withdraw Patent Listings from US Orange Book - Insight, China's Pharmaceutical Industry","description":"Three pharmaceutical companies, including the UK's GSK (NYSE: GSK), have responded to the Federal Trade Commission's (FTC) allegations of \"abusive\" patents by withdrawing several listings from the US Orange Book. This action follows the FTC's challenge in November against over 100 patents held by manufacturers of branded asthma inhalers, epinephrine autoinjectors, and other pharmaceutical products. The FTC claimed these patents were improperly or inaccurately listed in the US FDA\u2019s \"Approved Drug Products with Therapeutic Equivalence Evaluations,\" also known as the \"Orange Book,\" potentially obstructing the entry of generic competitors and inflating drug prices.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=8714","og_locale":"en_US","og_type":"article","og_title":"GSK and Peers Respond to FTC Criticism, Withdraw Patent Listings from US Orange Book","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=8714","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-02-20T14:01:31+00:00","article_modified_time":"2024-10-22T14:11:43+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=8714#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=8714"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GSK and Peers Respond to FTC Criticism, Withdraw Patent Listings from US Orange Book","datePublished":"2024-02-20T14:01:31+00:00","dateModified":"2024-10-22T14:11:43+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=8714"},"wordCount":302,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["GSK","NYSE: GSK"],"articleSection":["Company","Legal \/ IP","Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=8714#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=8714","url":"https:\/\/flcube.com\/?p=8714","name":"GSK and Peers Respond to FTC Criticism, Withdraw Patent Listings from US Orange Book - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-02-20T14:01:31+00:00","dateModified":"2024-10-22T14:11:43+00:00","description":"Three pharmaceutical companies, including the UK's GSK (NYSE: GSK), have responded to the Federal Trade Commission's (FTC) allegations of \"abusive\" patents by withdrawing several listings from the US Orange Book. This action follows the FTC's challenge in November against over 100 patents held by manufacturers of branded asthma inhalers, epinephrine autoinjectors, and other pharmaceutical products. The FTC claimed these patents were improperly or inaccurately listed in the US FDA\u2019s \"Approved Drug Products with Therapeutic Equivalence Evaluations,\" also known as the \"Orange Book,\" potentially obstructing the entry of generic competitors and inflating drug prices.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=8714#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=8714"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=8714#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GSK and Peers Respond to FTC Criticism, Withdraw Patent Listings from US Orange Book"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/8714","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=8714"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/8714\/revisions"}],"predecessor-version":[{"id":8715,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/8714\/revisions\/8715"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=8714"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=8714"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=8714"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}